niacinamide has been researched along with Hepatitis C, Chronic in 21 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Hepatitis C, Chronic: INFLAMMATION of the LIVER in humans that is caused by HEPATITIS C VIRUS lasting six months or more. Chronic hepatitis C can lead to LIVER CIRRHOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of this prospective, single-center, placebo-controlled, randomized, double-blind clinical study was to evaluate the effectiveness of transarterial chemoembolization (TACE) combined with sorafenib as a sequential treatment regimen in delaying time to progression (TTP) of intermediate-stage HCC in patients with chronic hepatitis C virus (HCV) infection." | 9.16 | Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial. ( Conteduca, V; Dammacco, F; Lauletta, G; Russi, S; Sansonno, D; Sansonno, L, 2012) |
| "The Sorafenib Hepatocellular Carcinoma (HCC) Assessment Randomized Protocol (SHARP) trial demonstrated that sorafenib improves overall survival and is safe for patients with advanced HCC." | 9.16 | Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. ( Beaugrand, M; Bolondi, L; Bruix, J; Craxi, A; Galle, PR; Gerken, G; Llovet, JM; Marrero, JA; Mazzaferro, V; Moscovici, M; Nadel, A; Porta, C; Raoul, JL; Sangiovanni, A; Santoro, A; Shan, M; Sherman, M; Voliotis, D, 2012) |
| "In patients with advanced hepatocellular carcinoma (HCC), the multikinase inhibitor sorafenib is the only systemic treatment that has been shown to increase overall survival." | 8.95 | Exceptional serological and radiological response to sorafenib in 2 patients with advanced hepatocellular carcinoma and chronic hepatitis C viral infection: case report and review of the literature. ( Atkin, C; Earwaker, P; Ma, YT; Pallan, A; Punia, P; Shetty, S, 2017) |
| "The multi-kinase inhibitor regorafenib (REG) was recently demonstrated to be effective in patients with sorafenib (SOR)-resistant hepatocellular carcinoma (HCC)." | 7.88 | Predominance of regorafenib over sorafenib: Restoration of membrane-bound MICA in hepatocellular carcinoma cells. ( Arai, J; Goto, K; Ito, S; Kaise, Y; Kato, N; Lim, LA; Matsubara, Y; Morimoto, S; Muroyama, R; Nakagawa, R; Stephanou, A; Tanoue, Y; Yoshida, H, 2018) |
| "To evaluate the impact of hepatitis C virus (HCV) eradication on the clinical outcome of patients with HCV-related advanced hepatocellular carcinoma (HCC) treated with sorafenib." | 7.85 | Impact of Hepatitis C Virus Eradication on the Clinical Outcome of Patients with Hepatitis C Virus-Related Advanced Hepatocellular Carcinoma Treated with Sorafenib. ( Aikata, H; Chayama, K; Hatooka, M; Hiramatsu, A; Honda, F; Imamura, M; Inagaki, Y; Kawakami, Y; Kawaoka, T; Kobayashi, T; Morio, K; Morio, R; Nagaoki, Y; Nakahara, T; Teraoka, Y; Tsuge, M, 2017) |
| "Sorafenib is a standard of care for advanced hepatocellular carcinoma (HCC)." | 7.83 | Effects of sorafenib combined with low-dose interferon therapy for advanced hepatocellular carcinoma: a pilot study. ( Arai, T; Atsukawa, M; Itokawa, N; Iwakiri, K; Kondo, C; Nakagawa, A; Okubo, T; Tsubota, A, 2016) |
| "Sorafenib, an oral multikinase inhibitor, has recentlybeen shown to improve overall survival in patients with advanced hepatocellular carcinoma (HCC) but only a handful of reports of complete remission on sorafenib have been issued." | 7.81 | Complete radiological response after sorafenib treatment for advanced hepato-cellular carcinoma. ( BelHadj, N; Ben Nejma, H; Bougassas, W; Cheikh, M; Elleuch, N; Ennaifer, R; Hefaiedh, R; Romdhane, H, 2015) |
| "Sorafenib (SO) was the first targeted agent to produce significant improvements in overall survival in patients with advanced hepatocellular carcinoma (HCC)." | 7.79 | Complete regression following sorafenib in unresectable, locally advanced hepatocellular carcinoma. ( Moroni, M; Zanlorenzi, L, 2013) |
| " The aim of this prospective, single-center, placebo-controlled, randomized, double-blind clinical study was to evaluate the effectiveness of transarterial chemoembolization (TACE) combined with sorafenib as a sequential treatment regimen in delaying time to progression (TTP) of intermediate-stage HCC in patients with chronic hepatitis C virus (HCV) infection." | 5.16 | Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial. ( Conteduca, V; Dammacco, F; Lauletta, G; Russi, S; Sansonno, D; Sansonno, L, 2012) |
| "The Sorafenib Hepatocellular Carcinoma (HCC) Assessment Randomized Protocol (SHARP) trial demonstrated that sorafenib improves overall survival and is safe for patients with advanced HCC." | 5.16 | Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. ( Beaugrand, M; Bolondi, L; Bruix, J; Craxi, A; Galle, PR; Gerken, G; Llovet, JM; Marrero, JA; Mazzaferro, V; Moscovici, M; Nadel, A; Porta, C; Raoul, JL; Sangiovanni, A; Santoro, A; Shan, M; Sherman, M; Voliotis, D, 2012) |
| "In patients with advanced hepatocellular carcinoma (HCC), the multikinase inhibitor sorafenib is the only systemic treatment that has been shown to increase overall survival." | 4.95 | Exceptional serological and radiological response to sorafenib in 2 patients with advanced hepatocellular carcinoma and chronic hepatitis C viral infection: case report and review of the literature. ( Atkin, C; Earwaker, P; Ma, YT; Pallan, A; Punia, P; Shetty, S, 2017) |
| "The multi-kinase inhibitor regorafenib (REG) was recently demonstrated to be effective in patients with sorafenib (SOR)-resistant hepatocellular carcinoma (HCC)." | 3.88 | Predominance of regorafenib over sorafenib: Restoration of membrane-bound MICA in hepatocellular carcinoma cells. ( Arai, J; Goto, K; Ito, S; Kaise, Y; Kato, N; Lim, LA; Matsubara, Y; Morimoto, S; Muroyama, R; Nakagawa, R; Stephanou, A; Tanoue, Y; Yoshida, H, 2018) |
| "To evaluate the impact of hepatitis C virus (HCV) eradication on the clinical outcome of patients with HCV-related advanced hepatocellular carcinoma (HCC) treated with sorafenib." | 3.85 | Impact of Hepatitis C Virus Eradication on the Clinical Outcome of Patients with Hepatitis C Virus-Related Advanced Hepatocellular Carcinoma Treated with Sorafenib. ( Aikata, H; Chayama, K; Hatooka, M; Hiramatsu, A; Honda, F; Imamura, M; Inagaki, Y; Kawakami, Y; Kawaoka, T; Kobayashi, T; Morio, K; Morio, R; Nagaoki, Y; Nakahara, T; Teraoka, Y; Tsuge, M, 2017) |
| "Sorafenib is a standard of care for advanced hepatocellular carcinoma (HCC)." | 3.83 | Effects of sorafenib combined with low-dose interferon therapy for advanced hepatocellular carcinoma: a pilot study. ( Arai, T; Atsukawa, M; Itokawa, N; Iwakiri, K; Kondo, C; Nakagawa, A; Okubo, T; Tsubota, A, 2016) |
| "Sorafenib, an oral multikinase inhibitor, has recentlybeen shown to improve overall survival in patients with advanced hepatocellular carcinoma (HCC) but only a handful of reports of complete remission on sorafenib have been issued." | 3.81 | Complete radiological response after sorafenib treatment for advanced hepato-cellular carcinoma. ( BelHadj, N; Ben Nejma, H; Bougassas, W; Cheikh, M; Elleuch, N; Ennaifer, R; Hefaiedh, R; Romdhane, H, 2015) |
| "Sorafenib (SO) was the first targeted agent to produce significant improvements in overall survival in patients with advanced hepatocellular carcinoma (HCC)." | 3.79 | Complete regression following sorafenib in unresectable, locally advanced hepatocellular carcinoma. ( Moroni, M; Zanlorenzi, L, 2013) |
| "Hepatocellular carcinoma is the leading cause of death in cirrhosis." | 2.46 | Review article: the management of hepatocellular carcinoma. ( Cabrera, R; Nelson, DR, 2010) |
| "The occurrence of hepatocellular carcinoma is about 3-15 % in patients with alcoholic liver disease." | 2.46 | [Hepatocellular carcinoma: occurrence, risk factors, biomarkers]. ( Fehér, J; Lengyel, G, 2010) |
| "At diagnosis Barcelona Clinic Liver Cancer staging (BCLC) was 0 (8%), A (48%), B (20%), C (17%), and D (7%)." | 1.48 | Determinants of survival following hepatocellular carcinoma in Egyptian patients with untreated chronic HCV infection in the pre-DAA era. ( Dore, GJ; Gomaa, A; Waked, I; Waziry, R, 2018) |
| "Mean survival in hepatocellular carcinoma remains low." | 1.42 | Multidisciplinary Approach in Hepatocellular Carcinoma in a Level II Hospital: The First Decade of Hospital Universitario Fundacion Alcorcon. ( Alonso López, S; Burgos, Rde L; Fernandez Cebrián, JM; Fernández Rodríguez, C; Gutiérrez Garcia, ML; LIedó Navarro, JL; Loinaz Segurola, C; Martel Villagrán, J; Martín Ríos, D; Ochando Cerdán, F, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 21 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arai, J | 1 |
| Goto, K | 1 |
| Stephanou, A | 1 |
| Tanoue, Y | 1 |
| Ito, S | 1 |
| Muroyama, R | 1 |
| Matsubara, Y | 1 |
| Nakagawa, R | 1 |
| Morimoto, S | 1 |
| Kaise, Y | 1 |
| Lim, LA | 1 |
| Yoshida, H | 1 |
| Kato, N | 1 |
| Waziry, R | 1 |
| Gomaa, A | 1 |
| Waked, I | 1 |
| Dore, GJ | 1 |
| Romantsov, MG | 1 |
| Petrov, AIu | 1 |
| Aleksandrova, LN | 1 |
| Sukhanov, DS | 1 |
| Kovalenko, AL | 1 |
| Moroni, M | 1 |
| Zanlorenzi, L | 1 |
| Albines, GS | 1 |
| Mesa, A | 1 |
| Fuentes-Martínez, N | 1 |
| Pérez, R | 1 |
| Fernández-Molina, J | 1 |
| Rodríguez, M | 1 |
| Varela, M | 1 |
| de León, FJ | 1 |
| Blanes, MM | 1 |
| Albares, MP | 1 |
| Berbegal, L | 1 |
| Elleuch, N | 1 |
| Ennaifer, R | 1 |
| Romdhane, H | 1 |
| Cheikh, M | 1 |
| Hefaiedh, R | 1 |
| Bougassas, W | 1 |
| Ben Nejma, H | 1 |
| BelHadj, N | 1 |
| Itokawa, N | 1 |
| Atsukawa, M | 1 |
| Tsubota, A | 1 |
| Okubo, T | 1 |
| Arai, T | 1 |
| Nakagawa, A | 1 |
| Kondo, C | 1 |
| Iwakiri, K | 1 |
| Loinaz Segurola, C | 1 |
| LIedó Navarro, JL | 1 |
| Burgos, Rde L | 1 |
| Martín Ríos, D | 1 |
| Ochando Cerdán, F | 1 |
| Alonso López, S | 1 |
| Martel Villagrán, J | 1 |
| Gutiérrez Garcia, ML | 1 |
| Fernandez Cebrián, JM | 1 |
| Fernández Rodríguez, C | 1 |
| Dika, IE | 1 |
| Harding, JJ | 1 |
| Abou-Alfa, GK | 1 |
| Atkin, C | 1 |
| Earwaker, P | 1 |
| Pallan, A | 1 |
| Shetty, S | 1 |
| Punia, P | 1 |
| Ma, YT | 1 |
| Kawaoka, T | 1 |
| Aikata, H | 1 |
| Teraoka, Y | 1 |
| Inagaki, Y | 1 |
| Honda, F | 1 |
| Hatooka, M | 1 |
| Morio, K | 1 |
| Morio, R | 1 |
| Kobayashi, T | 1 |
| Nagaoki, Y | 1 |
| Nakahara, T | 1 |
| Hiramatsu, A | 1 |
| Tsuge, M | 1 |
| Imamura, M | 1 |
| Kawakami, Y | 1 |
| Chayama, K | 1 |
| Cabrera, R | 1 |
| Nelson, DR | 1 |
| Wang, SX | 1 |
| Byrnes, A | 1 |
| Verma, S | 1 |
| Pancoast, JR | 1 |
| Rixe, O | 1 |
| Vagefi, PA | 1 |
| Hirose, R | 1 |
| Fehér, J | 1 |
| Lengyel, G | 1 |
| Villanueva, A | 1 |
| Newell, P | 1 |
| Hoshida, Y | 1 |
| Sacco, R | 1 |
| Bargellini, I | 1 |
| Gianluigi, G | 1 |
| Bertini, M | 1 |
| Bozzi, E | 1 |
| Altomare, E | 1 |
| Battaglia, V | 1 |
| Romano, A | 1 |
| Bertoni, M | 1 |
| Capria, A | 1 |
| Bresci, G | 1 |
| Bartolozzi, C | 1 |
| Sansonno, D | 1 |
| Lauletta, G | 1 |
| Russi, S | 1 |
| Conteduca, V | 1 |
| Sansonno, L | 1 |
| Dammacco, F | 1 |
| Endo, Y | 1 |
| Miyamoto, M | 1 |
| Koujima, T | 1 |
| Watanabe, Y | 1 |
| Kawai, T | 1 |
| Toda, K | 1 |
| Nobuhisa, T | 1 |
| Watanabe, T | 1 |
| Matsumoto, Y | 1 |
| Watanabe, N | 1 |
| Kai, K | 1 |
| Sato, S | 1 |
| Bruix, J | 1 |
| Raoul, JL | 1 |
| Sherman, M | 1 |
| Mazzaferro, V | 1 |
| Bolondi, L | 1 |
| Craxi, A | 1 |
| Galle, PR | 1 |
| Santoro, A | 1 |
| Beaugrand, M | 1 |
| Sangiovanni, A | 1 |
| Porta, C | 1 |
| Gerken, G | 1 |
| Marrero, JA | 1 |
| Nadel, A | 1 |
| Shan, M | 1 |
| Moscovici, M | 1 |
| Voliotis, D | 1 |
| Llovet, JM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective Cohort Study of Single Agent Memantine in Patients With Child-Pugh Score ≥ B7 Cirrhosis and Hepatocellular Carcinoma[NCT06007846] | Phase 2/Phase 3 | 12 participants (Anticipated) | Interventional | 2023-07-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for niacinamide and Hepatitis C, Chronic
| Article | Year |
|---|---|
[Pathogenetic correction of metabolic disturbances in chronic liver affections].
Topics: Apoptosis; Chronic Disease; Drug Combinations; Flavin Mononucleotide; Glutathione Disulfide; Hepatit | 2012 |
Hepatocellular carcinoma in patients with HIV.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Coinfection; Hepatitis B, Chronic; Hepatitis C, Ch | 2017 |
Exceptional serological and radiological response to sorafenib in 2 patients with advanced hepatocellular carcinoma and chronic hepatitis C viral infection: case report and review of the literature.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Hepatitis C, Chr | 2017 |
Review article: the management of hepatocellular carcinoma.
Topics: Ablation Techniques; Adult; Antineoplastic Agents; Asian People; Benzenesulfonates; Biopsy; Black Pe | 2010 |
Downstaging of hepatocellular carcinoma prior to liver transplant: is there a role for adjuvant sorafenib in locoregional therapy?
Topics: alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Hepatitis C | 2010 |
[Hepatocellular carcinoma: occurrence, risk factors, biomarkers].
Topics: Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Copper; Deve | 2010 |
Inherited hepatocellular carcinoma.
Topics: Algorithms; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; | 2010 |
2 trials available for niacinamide and Hepatitis C, Chronic
| Article | Year |
|---|---|
Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progress | 2012 |
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.
Topics: Aged; Alcoholism; Antineoplastic Agents; Carcinoma, Hepatocellular; Diarrhea; Disease Progression; F | 2012 |
12 other studies available for niacinamide and Hepatitis C, Chronic
| Article | Year |
|---|---|
Predominance of regorafenib over sorafenib: Restoration of membrane-bound MICA in hepatocellular carcinoma cells.
Topics: ADAM Proteins; ADAM10 Protein; Amyloid Precursor Protein Secretases; Carcinoma, Hepatocellular; Depr | 2018 |
Determinants of survival following hepatocellular carcinoma in Egyptian patients with untreated chronic HCV infection in the pre-DAA era.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; | 2018 |
Complete regression following sorafenib in unresectable, locally advanced hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Italy; Liver Neoplasms | 2013 |
Occurrence of hepatocellular carcinoma upon advanced liver fibrosis thirteen years after achieving sustained virological response to hepatitis C: how long surveillance should be maintained?
Topics: Antineoplastic Agents; Antiviral Agents; Biomarkers; Biopsy; Carcinoma, Hepatocellular; Genotype; He | 2015 |
Cutaneous metastasis from hepatocellular carcinoma after a percutaneous interventional procedure.
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Diathermy; Ethan | 2015 |
Complete radiological response after sorafenib treatment for advanced hepato-cellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Hepatitis C, Chronic; Humans; Liver | 2015 |
Effects of sorafenib combined with low-dose interferon therapy for advanced hepatocellular carcinoma: a pilot study.
Topics: Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biomark | 2016 |
Multidisciplinary Approach in Hepatocellular Carcinoma in a Level II Hospital: The First Decade of Hospital Universitario Fundacion Alcorcon.
Topics: Ablation Techniques; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chem | 2015 |
Impact of Hepatitis C Virus Eradication on the Clinical Outcome of Patients with Hepatitis C Virus-Related Advanced Hepatocellular Carcinoma Treated with Sorafenib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Disease | 2017 |
Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib: a case report.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Dosage Calculations; Hepacivirus; Hepatitis | 2010 |
Complete response for advanced liver cancer during sorafenib therapy: case report.
Topics: Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatoce | 2011 |
[A case of advanced hepatocellular carcinoma with portal vein invasion successfully treated by sorafenib].
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Hepatitis C, Chronic; Hum | 2012 |